Kirsten Drejer is a highly respected name in pharma and biotech community. She is best known for being co-founder and CEO of Symphogen A/S. Prior to co-founding Symphogen in 2000, Kirsten held several scientific and managerial positions at Novo Nordisk A/S, including four years as Director of Diabetes Discovery, and three years as Corporate Facilitator. Kirsten is member of the board of directors of a number of biotech and pharma companies, including Zealand Pharma and Antag Therapeutics.